Related Experiment Video
Updated: Feb 3, 2026
Isolation of Stem Cells from Human Pancreatic Cancer Xenografts
Published on: September 26, 2010
CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic
Keisuke Kuhara1,2, Kazuhiro Tokuda3, Takao Kitagawa4
1Division of Oral and Maxillofacial Surgery, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Background/Aim:
We have previously reported that treatment of pancreatic cancer cells with active hexose-correlated compound (AHCC), an extract of a basidiomycete mushroom, decreases the levels of tumor-associated proteins including heat-shock protein 27 (HSP27), heat shock factor 1 (HSF1) and sex-determining region Y-box 2 (SOX2). The transmembrane glycoprotein, CUB domain-containing protein 1 (CDCP1) has been reported to be up-regulated in various cancers, and be associated with invasion and metastasis. The aim of this study was to examine the effect of AHCC on the expression of CDCP1 in KLM1-R cells.
Materials And Methods:
Gemcitabine-resistant pancreatic cancer cells (KLM1-R) were treated with AHCC (10 mg/ml) for 48 h. Western blot analysis of cell extracts with anti-CDCP1 or anti-actin antibodies was performed to assess the expression of CDCP1.
Results:
Expression of CDCP1 was reduced by AHCC treatment of KLM1-R cells, whereas expression of actin was not affected. The ratio of intensities of CDCP1/actin in AHCC-treated KLM1-R cells was significantly suppressed (p<0.05) compared to untreated cells.
Conclusion:
AHCC down-regulated CDCP1 expression and inhibited the malignant progression of pancreatic cancer cells.
Insights
Active hexose-correlated compound (AHCC) reduces CUB domain-containing protein 1 (CDCP1) expression in gemcitabine-resistant pancreatic cancer cells. This finding suggests AHCC may inhibit pancreatic cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Active hexose-correlated compound (AHCC), a mushroom extract, previously lowered tumor-associated proteins in pancreatic cancer.
- CUB domain-containing protein 1 (CDCP1) is a transmembrane glycoprotein often upregulated in cancers, linked to invasion and metastasis.
Purpose of the Study:
- To investigate the effect of AHCC on CDCP1 expression in gemcitabine-resistant pancreatic cancer cells (KLM1-R).
Main Methods:
- Gemcitabine-resistant pancreatic cancer cells (KLM1-R) were treated with AHCC (10 mg/ml) for 48 hours.
- Western blot analysis was used to assess CDCP1 expression using anti-CDCP1 and anti-actin antibodies.
Main Results:
- AHCC treatment significantly reduced CDCP1 expression in KLM1-R cells.
- Actin expression remained unaffected, indicating specific downregulation of CDCP1.
- The ratio of CDCP1/actin intensities was significantly suppressed in AHCC-treated cells (p<0.05).
Conclusions:
- AHCC effectively down-regulates CDCP1 expression in pancreatic cancer cells.
- This downregulation suggests AHCC may inhibit the malignant progression of pancreatic cancer.
Related Concept Videos
02:26Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
02:58Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
02:58Regulated Protein Degradation
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
02:26Conservation of Protein Domains
02:20Correlations